| Schedule of financial information by reportable segment |
Following is financial information relating to the operating segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended June 30, |
|
|
2024 |
|
2023 |
|
2022 |
Net sales: |
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
830,902 |
|
$ |
845,747 |
|
$ |
832,311 |
Diagnostics and Genomics |
|
|
326,392 |
|
|
292,602 |
|
|
274,843 |
Other revenue(1) |
|
|
4,153 |
|
|
— |
|
|
— |
Intersegment |
|
|
(2,387) |
|
|
(1,647) |
|
|
(1,555) |
Consolidated net sales |
|
$ |
1,159,060 |
|
$ |
1,136,702 |
|
$ |
1,105,599 |
|
|
|
|
|
|
|
|
|
|
Operating income: |
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
354,775 |
|
$ |
373,684 |
|
$ |
377,623 |
Diagnostics and Genomics |
|
|
24,546 |
|
|
43,037 |
|
|
48,977 |
Segment operating income |
|
|
379,321 |
|
|
416,721 |
|
|
426,600 |
Costs recognized on sale of acquired inventory |
|
|
(729) |
|
|
(400) |
|
|
(1,596) |
Amortization of intangibles |
|
|
(78,318) |
|
|
(76,413) |
|
|
(73,054) |
Impact of partially-owned consolidated subsidiaries(2) |
|
|
— |
|
|
647 |
|
|
(2,393) |
Acquisition related expenses and other |
|
|
(6,980) |
|
|
9,965 |
|
|
19,070 |
Certain Litigation Charges |
|
|
(3,506) |
|
|
— |
|
|
— |
Impairment of assets held-for-sale |
|
|
(21,963) |
|
|
— |
|
|
— |
Eminence impairment |
|
|
— |
|
|
— |
|
|
(18,715) |
Stock based compensation, inclusive of employer taxes |
|
|
(40,277) |
|
|
(41,217) |
|
|
(46,401) |
Restructuring and restructuring-related costs |
|
|
(12,245) |
|
|
(3,829) |
|
|
(1,640) |
Corporate general, selling, and administrative expenses |
|
|
(9,142) |
|
|
(6,530) |
|
|
(5,281) |
Impact of business held-for-sale(1) |
|
|
525 |
|
|
— |
|
|
— |
Consolidated operating income |
|
$ |
206,686 |
|
$ |
298,944 |
|
$ |
296,590 |
|
(1) |
Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. For the year ended June 30, 2024, includes the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria. |
|
(2) |
Includes the annual results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023. |
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended June 30, |
|
|
2024 |
|
2023 |
|
2022 |
Consumables revenue - Protein Sciences |
|
$ |
657,679 |
|
$ |
665,301 |
|
$ |
646,952 |
Consumables revenue - Diagnostics and Genomics |
|
|
266,348 |
|
|
252,432 |
|
|
243,922 |
Consumables revenue - Other revenue(1) |
|
|
4,153 |
|
|
— |
|
|
— |
Total consumable revenue |
|
$ |
928,180 |
|
$ |
917,733 |
|
$ |
890,874 |
(1)Includes the results of a business that has met the held-for-sale criteria since December 31, 2023.
|
|
|
|
|
|
|
|
|
Year ended June 30, |
|
|
2024 |
|
2023 |
Long-lived assets: |
|
|
|
|
|
|
United States and Canada |
|
$ |
211,597 |
|
$ |
203,657 |
Europe |
|
|
27,862 |
|
|
19,263 |
Asia |
|
|
11,695 |
|
|
3,280 |
Total long-lived assets |
|
$ |
251,154 |
|
$ |
226,200 |
Intangible assets: |
|
|
|
|
|
|
United States and Canada |
|
$ |
443,740 |
|
$ |
529,652 |
Europe |
|
|
63,138 |
|
|
4,553 |
Asia |
|
|
203 |
|
|
440 |
Total intangible assets |
|
$ |
507,081 |
|
$ |
534,645 |
|